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In this issue of Kardiologia Polska, Kiełbasa et 
al. [1] evaluated the risk of atrial fibrillation 
(AF) recurrence in a cohort of 417 consecutive 
patients with paroxysmal AF undergoing cry-
oballoon ablation for pulmonary vein isolation 
(PVI). The left atrium was accessed transseptally 
in all cases; median follow-up time was 2 years 
(maximum 7 years). Recurrent AF was ascer-
tained by 24–72-hour Holter monitoring at 3 and 
6–9 months after ablation. Further electrocar-
diographic monitoring was advised yearly or 
in case of palpitations. Stepwise multivariable 
Cox regression analysis identified variables inde-
pendently associated with the risk of recurrent 
AF. Overall, AF recurrence was documented 
in 25.7% of the study cohort after 11 056 pa-
tient months of follow-up. Left atrial diameter 
>40 mm (adjusted hazard ratio [aHR] 1.88, 95% 
CI, 1.23–2.87; P = 0.004), low left atrial append-
age flow velocity defined as <45 cm/s (aHR 1.63, 
95% CI, 1.06–2.49; P = 0.02), and the presence of 
a patent foramen ovale (PFO) (aHR 1.79, 95% CI, 
1.02–3.15; P = 0.04) were independently asso-
ciated with the risk of AF recurrence. This study 
has several strengths, including the fairly large 
size, and adjustment of the multivariable models 
for all clinically relevant variables. The authors 
correctly acknowledged most of its limitations, 
including that it is a retrospective study based 
on data from a single center. The dichotomiza-
tion of left atrial velocity may explain its signifi-
cant association with AF recurrence. The authors 
used a cutoff derived from the same cohort in 
which they subsequently ran the multivariable 
regression analyses, so a significant association 
is not surprising. 
The association between increased left 
atrial size and AF recurrence post ablation has 
been well-documented in previous studies [2]. 
In line with the findings of the study by Kiełbasa 
et al. [1], reduced left atrial appendage velocity 
has been found to be associated with increased 
risk of AF after cardiac surgery [3]. In our view, 
the most intriguing finding of this study is the 
79% increased risk of AF recurrence associated 
with the presence of a PFO. This finding adds to 
consideration of important issues about the as-
sociation between AF and PFO that we discuss 
below: (a) the high prevalence of concurrent AF 
and PFO, and (b) the elevated risk of incident 
AF post PFO closure. 
At least two studies have documented that 
catheter probing performed during pulmonary 
vein isolation procedures has a 2–3-fold higher 
PFO detection yield than transesophageal 
echocardiography (TEE) [4–6]. We hypothe-
sized in 2020 that AF may be more common 
in patients with PFO [6]. In a study of the Risk 
of Paradoxical Embolism (ROPE) score, 40% 
of patients with ESUS had a PFO, and AF was 
observed in 20.5% of PFO patients with a ROPE 
score of 0–6, with a 53% risk of recurrent stroke 
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over 10 years [7]. This association supports the suggestion 
that some patients with PFO might be treated better with 
anticoagulation than by closure of the PFO [8]. 
Since a PFO is present in ~25% of the population [9], it is 
surprising that Kielbasa et al. [1] found a PFO in only 12.7% 
of their patients, relying on TEE for diagnosis. Daher et al. 
[5] reported that among AF patients referred for PVI, 57% 
had a PFO identified by catheter probing, but only 18.7% 
of patients had a PFO diagnosed by TEE. Small PFOs are less 
likely to be identified with echocardiography. Transcranial 
Doppler saline studies are more sensitive than echocar-
diography [10], perhaps in part because the adequacy of 
the Valsalva maneuver can be verified by the drop in blood 
velocity in the middle cerebral artery. It is possible that the 
pressure exerted on the interatrial septum with the ablation 
catheter may open otherwise collapsed PFOs. 
The embolic risk of PFOs that are visualized only by 
catheter probing is likely low, although it has never been 
investigated. Alternatively, it is also possible that the PFO 
itself generates some degree of atrial vulnerability [11], 
creating the necessary physiological environment for the 
occurrence of AF, as mentioned by Kiełbasa et al. [1].
It can be hypothesized that individuals undergoing PFO 
closure have a specific susceptibility to develop cardiac 
arrhythmias triggered by the periprocedural manipulation 
of the left atrium. Left atrial trauma could result in local 
inflammation, a recognized trigger for AF [12]. Similarly, 
changes in left atrial intracavitary pressures and sudden 
distortions of its tridimensional architecture caused by 
the occlusion of the PFO could initiate AF. Although these 
mechanisms are plausible, they are likely influenced by oth-
er factors. First, as suggested by the frequent coexistence 
of paroxysmal AF and PFO in the study of Kiełbasa et al. [1], 
AF may constitute a latent subclinical condition in patients 
with PFO that becomes more active and clinically evident 
after the PFO is closed. In this hypothetical scenario, a PFO 
closure may lower the threshold for the occurrence of AF 
paroxysms in patients with otherwise relatively inactive 
and subclinical AF. Additional possible factors explaining 
the elevated risk of paroxysmal AF after PFO closure are age 
and the presence of vascular risk factors or cardiovascular 
comorbidities. If the procedure itself was the only cause of 
AF in patients with PFO, the associated risk of AF relative to 
medical treatment alone would be expected to be similar 
in randomized clinical trials of PFO closure for secondary 
stroke prevention and clinical improvement of migraine 
with aura. However, in clinical trials of PFO closure for 
secondary stroke prevention, the risk of incident post-pro-
cedural AF was 5x higher compared to medical treatment 
[13], whereas in clinical trials of migraine prevention, there 
were no differences in the risk of incident AF between PFO 
closure and medical treatment [14]. Thus, discrepancies in 
the risk of Incident AF post PFO closure between patients 
with stroke and migraine are possibly explained by a higher 
age and a greater burden of risk factors and vascular co-
morbidities in stroke patients. This is consistent with the 
observation by Strambo et al. [7] that among PFO patients 
with a ROPE score of 7–10, only 3.1% had new-onset AF, 
and only 1.7% had stroke recurrence over 10 years. 
The study by Kiełbasa et al. [1] provides additional 
evidence on the intriguing association between PFO and 
AF with a novel perspective that requires further testing 
in independent cohorts. 
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